1-Cyclopropionyl d-lysergic acids diethylamide, also known as 1cP -LSD, is a less-known novel psychedelic compound of the lysergamide family. It is chemically identical to LSD and other LSD analogues such as 1B-LSD and ALD-52. Although its mechanism of action has not been well studied, it is believed to stimulate serotonin receptors in certain parts of the brain.
It is not known where 1cP-LSD originated. 1cP-LSD was banned in Germany in 2018. 1cP-LSD made its debut on the online market for research chemicals in 2019. It was promoted as an alternative to LSD and 1P, just like other LSD analogs.
Subjective effects include time distortion, open and closed eyes, conceptual thinking and enhanced introspection. They can also cause ego loss. One study showed that 1cP-LSD incubated with human serum produced LSD. This suggests that the drug may be a prodrug for LSD. This theory seems to be supported by anecdotal evidence, as most users report almost identical effects to LSD.
1cP-LSD, which was synthesized and discovered in the Netherlands in 2019, first made its debut on the online market for research chemicals in July 2019. It was made shortly after Germany banned 1P-LSD. This is one of many designer LSD analogs which have been on the market since the mid-2010s. They include AL-LAD and ETH-LAD as well as ALD-52.
1cP-LSD, a semisynthetic compound belonging to the lysergamide group, is one example. It is very similar to LSD, and its name is derived from the cyclopropionyl ring bound to the nitrogen in the polycyclic-indole group. The cyclopropionyl groups consist of a carbonyl-ring with C3H6 and an amino group. 1cP-LSD has a polycyclic structure that includes a bicyclic indole and a bicyclic quinone group. An N,N,-diethyl carbboxamide is attached at carbon 8 of the Quinoline.
The properties of 1cP-LSD are almost identical to the properties of LSD 25 or 1P-LSD. An alkylcarbonyl ring has the empirical formula C4H7O while the cyclopropylcarbonyl ring corresponds to the molecular formula C4H5O. Therefore, the NpSG amending Regulation does not affect the substance 1cP – LSD.
Because of its structural similarities to LSD, 1cP -LSD may act as a partial agonist for the 5-HT2A receptor. Its efficacy at 5-HT2A receptors throughout the brain is thought to be the main source of psychedelic effects. 1cP-LSD may also have binding activity to a variety of monoamine receptors such as dopamine or norepinephrine. These claims are not supported by data.
The majority of serotonergic psychedelics do not have a significant dopaminergic component, so 1-cP-LSD may be atypical. Its psychoactive effects may be due to the agonism of D2 receptor. 1cP-LSD binds almost all serotonin receptor types, except the 5-HT3 or 5-HT4 receptors. These receptors are too weakly affected to be activated by brain concentrations of 10-20 nM. Recreational doses may affect 5-HT1A, 5-HT2A, 5-HT2B (Ki=2.9nM), 5HT2B (Ki=4.9nM),5-HT2C (Ki=23nM), 5HT5A (Ki=9nM),5-HT6 receptors (5HT6 (Ki=2.3nM)).
1cP-LSD, a biased agonist, induces a conformation within serotonin receptors which preferentially recruits activating G proteins over b-arrestin. The crystal structure of 5-HT2B bound with 1cP-LSD shows an extracellular loop which forms a lid on the diethylamide side of the binding cavity. This is what explains the slow rate at which serotonin receptors are unbound.